Verjee Rehan purchased $20K of TYRA

Verjee Rehan purchased 972 shares of Tyra Biosciences, Inc. (TYRA) at $20.58 on 2026-09-09.

Original reporting
SEC EDGAR · Verjee Rehan
Published Sep 11, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TYRA
Neutral
high confidence
Mentioned
$TYRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TYRANeutralLow
01

Why it matters

The filing provides a first‑report of a director's modest share purchase, offering limited insight for traders.

02

Market read

Insider purchase is small; unlikely to affect TYRA's stock price or broader market.

03

What to watch

No additional corporate actions or material news accompany the filing.

Relevance 4/10Novelty 4/10Timing: filed Sep 11 2026

Background

SEC Form 4 filing discloses insider transactions; directors' purchases are monitored for potential signals.

Company-level read

Ticker impact

$TYRANeutralHigh confidence
Context

Director Verjee Rehan bought 972 shares of TYRA for $20,000 in an open‑market purchase filed on Sep 11, 2026.

Expected impact

minimal impact, possible slight positive bias

Evidence & confidence

The transaction size is modest relative to market cap and represents a routine 10b5‑1‑free purchase.

Market effects

None

None

None

Counterpoint

The purchase may signal confidence, but size is too small to be meaningful.

Key entities

  • Tyra Biosciences, Inc.

    Biotech firm listed on NASDAQ under TYRA.

  • Verjee Rehan

    Director of Tyra Biosciences who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.

$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.

$TYRAMedAI 8/10

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.